MDGL Stock Quote Price and Forecast | CNN

MDGL

Madrigal Pharmaceuticals, Inc.

Key terms

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Key terms

Smart score

Apr 09 8:15pm ET Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Madrigal Pharmaceuticals (MDGL) by TipRanks Mar 25 6:50am ET Analysts Conflicted on These Healthcare Names: Masimo (MASI), ImmunityBio (IBRX) and Madrigal Pharmaceuticals (MDGL) by TipRanks Mar 20 8:13am ET Madrigal Pharmaceuticals price target raised to $405 from $325 at Evercore ISI by TipRanks Mar 19 5:58am ET Madrigal Pharmaceuticals 750K share Spot Secondary priced at $260.00 by TipRanks Mar 19 2:00am ET Analysts Are Bullish on These Healthcare Stocks: Cullinan Management (CGEM), Gilead Sciences (GILD) by TipRanks Mar 18 4:05pm ET Madrigal Pharmaceuticals announces $500M common stock offering by TipRanks Mar 18 11:03am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Mar 15 10:26am ET BofA says 89bio should trade with strength after ‘win for entire MASH space’ by TipRanks Mar 15 9:41am ET DoorDash upgraded, GM initiated: Wall Street’s top analyst calls by TipRanks Mar 15 9:40am ET Unusually active option classes on open March 15th by TipRanks Mar 15 8:13am ET Madrigal Pharmaceuticals price target raised to $410 from $337 at UBS by TipRanks Mar 15 7:51am ET Madrigal Pharmaceuticals price target raised to $375 from $320 at Oppenheimer by TipRanks Mar 15 7:30am ET Madrigal Pharmaceuticals price target raised to $390 from $349 at TD Cowen by TipRanks Mar 15 7:17am ET Approval of Madrigal’s Rezdiffra positive for Viking and MASH space, says Stifel by TipRanks Mar 15 7:17am ET Madrigal Pharmaceuticals price target raised to $377 from $338 at Canaccord by TipRanks Mar 15 7:14am ET Viking Therapeutics price target raised to $100 from $86 at BTIG by TipRanks Mar 15 7:01am ET Madrigal Pharmaceuticals price target raised to $389 from $382 at Citi by TipRanks Mar 15 6:17am ET Madrigal price target raised to $425 from $405 at H.C. Wainwright by TipRanks Mar 15 6:12am ET Madrigal Pharmaceuticals price target raised to $397 from $351 at JMP Securities by TipRanks Mar 15 4:52am ET Madrigal Pharmaceuticals upgraded to Neutral from Sell at B. Riley by TipRanks Mar 14 4:45pm ET Madrigal Pharmaceuticals trading resumes by TipRanks Mar 14 4:37pm ET Madrigal to resume trading at 4:45 PM ET after FDA approval by TipRanks Mar 14 4:30pm ET Madrigal label for Rezdiffra ‘best case scenario,’ say Piper Sandler by TipRanks Mar 14 4:27pm ET Madrigal announces FDA accelerated approval of Rezdiffra by TipRanks Mar 14 3:47pm ET FDA approves Madrigal Pharmaceuticals’ Rezdiffra by TipRanks Mar 14 3:29pm ET Madrigal Pharmaceuticals trading halted, news pending by TipRanks Mar 12 6:25am ET Buy Rating Affirmed for Madrigal Pharmaceuticals Amidst Resmetirom’s FDA Approval and First-Mover Advantage by TipRanks Mar 12 6:17am ET Madrigal Pharmaceuticals price target raised to $405 from $275 at H.C. Wainwright by TipRanks Mar 08 8:00am ET Analysts Are Bullish on These Healthcare Stocks: Prestige Consumer Healthcare (PBH), Madrigal Pharmaceuticals (MDGL) by TipRanks Mar 08 7:44am ET Madrigal Pharmaceuticals price target raised to $338 from $336 at Canaccord by TipRanks Mar 07 7:41am ET Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biomea Fusion (BMEA) and Jasper Therapeutics (JSPR) by TipRanks

Apr 05 7:15am ET Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics by Motley Fool Apr 03 8:45am ET 1 No-Brainer Growth Stock to Buy Now by Motley Fool Mar 29 9:00am ET Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals by Motley Fool Mar 29 4:43am ET Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? by Motley Fool Mar 26 9:53am ET Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock by Motley Fool Mar 22 6:15am ET This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy? by Motley Fool Mar 19 5:50am ET Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? by Motley Fool Mar 17 5:50am ET Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? by Motley Fool Mar 09 5:52am ET Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon. by Motley Fool Mar 05 6:03am ET 1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247? by Motley Fool

No recent press releases are available for MDGL

1-year income & revenue

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Donald Trump might no longer own a majority of TMTG after a new public share offering.

Joe Raedle/Getty Images

Trump stock tanks after announcing massive share sale

1040 US Individual Income Tax Return Form

Nora Carol Photography/Moment RF/Getty Images

Three ways investors can minimize their tax payments

People walk past the New York Stock Exchange (NYSE) on April 10, 2024 in New York City.

Spencer Platt/Getty Images

Dow closes nearly 500 points lower on fears of potential Iranian attack on Israel

JPMorgan beat earnings expectations this Friday, unofficially kicking off the first quarter earnings season.

Win McNamee/Getty Images

Jamie Dimon says chance of a bad economy is ‘higher than other people think’